BACKGROUND: Approximately one fourth of bone and soft-tissue sarcomas recur after prior treatment. GLV-1h68 is a recombinant, replication-competent vaccinia virus that has been shown to have oncolytic effects against many human cancer types. We sought to determine whether GLV-1h68 could selectively target and lyse a panel of human bone and soft-tissue sarcoma cell lines in vitro and in vivo. METHODS: GLV-1h68 was tested in a panel of four cell lines including: fibrosarcoma HT-1080, osteosarcoma U-2OS, fibrohistiocytoma M-805, and rhabdomyosarcoma HTB-82. Gene expression, infectivity, viral proliferation, and cytotoxicity were characterized in vitro. HT-1080 xenograft flank tumors grown in vivo were injected intratumorally with a single dose of GLV-1h68. RESULTS: All four cell lines supported robust viral transgene expression in vitro. At a multiplicity of infection (MOI) of five, GLV-1h68 was cytotoxic to three cell lines, resulting in >80% cytotoxicity over 7 d. In vivo, a single injection of GLV-1h68 into HT-1080 xenografts exhibited localized intratumoral luciferase activity peaking at d 2-4, with gradual resolution over 8 d and no evidence of spread to normal tissues. Treated animals exhibited near-complete tumor regression over a 28-d period without observed toxicity. CONCLUSION: GLV-1h68 has potent direct oncolytic effects against human sarcoma in vitro and in vivo. Recombinant vaccinia oncolytic virotherapy could provide a new platform for the treatment of patients with bone and soft tissue sarcomas. Future clinical trials investigating oncolytic vaccinia as a therapy for sarcomas are warranted.
BACKGROUND: Approximately one fourth of bone and soft-tissue sarcomas recur after prior treatment. GLV-1h68 is a recombinant, replication-competent vaccinia virus that has been shown to have oncolytic effects against many humancancer types. We sought to determine whether GLV-1h68 could selectively target and lyse a panel of human bone and soft-tissue sarcoma cell lines in vitro and in vivo. METHODS:GLV-1h68 was tested in a panel of four cell lines including: fibrosarcoma HT-1080, osteosarcomaU-2OS, fibrohistiocytoma M-805, and rhabdomyosarcoma HTB-82. Gene expression, infectivity, viral proliferation, and cytotoxicity were characterized in vitro. HT-1080 xenograft flank tumors grown in vivo were injected intratumorally with a single dose of GLV-1h68. RESULTS: All four cell lines supported robust viral transgene expression in vitro. At a multiplicity of infection (MOI) of five, GLV-1h68 was cytotoxic to three cell lines, resulting in >80% cytotoxicity over 7 d. In vivo, a single injection of GLV-1h68 into HT-1080 xenografts exhibited localized intratumoral luciferase activity peaking at d 2-4, with gradual resolution over 8 d and no evidence of spread to normal tissues. Treated animals exhibited near-complete tumor regression over a 28-d period without observed toxicity. CONCLUSION:GLV-1h68 has potent direct oncolytic effects against humansarcoma in vitro and in vivo. Recombinant vaccinia oncolytic virotherapy could provide a new platform for the treatment of patients with bone and soft tissue sarcomas. Future clinical trials investigating oncolytic vaccinia as a therapy for sarcomas are warranted.
Authors: Patrick Baril; Yann Touchefeu; Jeannette Cany; Yan Cherel; Steve H Thorne; Lucile Tran; Sophie Conchon; Georges Vassaux Journal: J Gene Med Date: 2011-12 Impact factor: 4.565
Authors: Steve H Thorne; Tae-Ho H Hwang; William E O'Gorman; David L Bartlett; Shizuko Sei; Femina Kanji; Christopher Brown; Joel Werier; Jin-Han Cho; Dong-Ewon Lee; Yaohe Wang; John Bell; David H Kirn Journal: J Clin Invest Date: 2007-11 Impact factor: 14.808
Authors: Qian Zhang; Yong A Yu; Ena Wang; Nanhai Chen; Robert L Danner; Peter J Munson; Francesco M Marincola; Aladar A Szalay Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701
Authors: Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng Journal: Gynecol Oncol Date: 2014-01-14 Impact factor: 5.482
Authors: Sepideh Gholami; Chun-Hao Chen; Laurence J Belin; Emil Lou; Sho Fujisawa; Caroline Antonacci; Amanda Carew; Nanhai G Chen; Marina De Brot; Pat B Zanzonico; Aladar A Szalay; Yuman Fong Journal: Breast Cancer Res Date: 2013-03-18 Impact factor: 6.466
Authors: Klaas Ehrig; Mehmet O Kilinc; Nanhai G Chen; Jochen Stritzker; Lisa Buckel; Qian Zhang; Aladar A Szalay Journal: J Transl Med Date: 2013-03-26 Impact factor: 5.531